Compare Recursion Pharmaceuticals Inc (RXRX) vs J M Smucker Co (SJM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs J M Smucker Co — how do they compare? Recursion Pharmaceuticals Inc trades at $4.01 (market cap $2.14B), while J M Smucker Co trades at $119 (market cap $12.76B). The key difference: J M Smucker Co is far larger — about 6× Recursion Pharmaceuticals Inc's market cap, and J M Smucker Co pays a 3.75% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Recursion Pharmaceuticals Inc for 22 Days and J M Smucker Co for 74 Days on average.
| RXRX | SJM | |
|---|---|---|
Market Cap | $2.14B | $12.76B |
Volume | 30,789,535 | 1,300,545 |
Sector | Health | Consumer Staples |
52-Week High | $6.79 | $132.34 |
52-Week Low | $2.84 | $89.53 |
Typical Hold Time | 22 Days | 74 Days |
Enterprise Value | $1.66B | $19.61B |
Dividend Yield | — | 3.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $4.27, down 7.78% today, with technical indicators showing a bullish trend despite recent weakness. The company reported Q2 2026 earnings miss after two consecutive beats, with revenue declining to $54 million in 2026 from $74 million in 2025. While maintaining a negative net income margin of -961.97%, RXRX continues to expand its AI-powered drug discovery platform through strategic partnerships with Tempus and Roche.
The stock presents high-risk growth potential with strong analyst support (40% buy rating) but faces significant execution challenges. Investment appeal hinges on successful pipeline development and commercialization of AI drug discovery technology, though persistent losses and declining revenue create substantial downside risk for shareholders.
SJM trades at $115.93, down 0.74% on the day, with a bearish technical signal and recent earnings beats. The company reported a net loss of $1.23 billion in 2025 despite revenue growth to $8.73 billion, though 2026 forecasts show a return to profitability. Analyst consensus is bullish with a $138.23 price target, and a $1.12 dividend is scheduled for September 2026.
The stock presents a mixed outlook: strong analyst support and dividend yield offer upside, but high P/E of 55.8 and recent net losses pose valuation and execution risks. Key catalysts include sustained earnings growth and margin improvement, while competitive pressures and debt levels remain concerns for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About J M Smucker Co
J.M. Smucker is a packaged food company that primarily operates in the U.S. retail channel (87% of fiscal 2022 revenue), but also in U.S. food-service (7%), and international (6%). Its largest segment is pet food and treats (36% of 2022 revenue), with popular brands such as Milk-Bone, Meow Mix, 9Lives, Kibbles 'n Bits, Nature's Recipe, and Rachael Ray Nutrish. Its second-largest category is coffee (35% across channels) with the number-two brand Folgers and number-six Dunkin'. Other large categories are peanut butter (10%), with number-one Jif, fruit spreads (5%) with number-one Smucker's, and frozen hand-held foods (6%) with number-one Uncrustables.
Read more on SJM →
